243 related articles for article (PubMed ID: 37530847)
1. The association between proton pump inhibitors and hyperparathyroidism: a potential mechanism for increased fracture-results of a large observational cohort study.
Fitzpatrick D; Lannon R; Laird E; Ward M; Hoey L; Hughes CF; Strain JJ; Cunningham C; McNulty H; Molloy AM; McCarroll K
Osteoporos Int; 2023 Nov; 34(11):1917-1926. PubMed ID: 37530847
[TBL] [Abstract][Full Text] [Related]
2. Hyperparathyroidism Associated with Long-Term Proton Pump Inhibitors Independent of Concurrent Bisphosphonate Therapy in Elderly Adults.
Hinson AM; Wilkerson BM; Rothman-Fitts I; Riggs AT; Stack BC; Bodenner DL
J Am Geriatr Soc; 2015 Oct; 63(10):2070-3. PubMed ID: 26415604
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
[TBL] [Abstract][Full Text] [Related]
4. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
[TBL] [Abstract][Full Text] [Related]
5. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
[TBL] [Abstract][Full Text] [Related]
6. Secondary hyperparathyroidism: Predictors and relationship with vitamin D status, bone turnover markers and bone mineral density.
Fitzpatrick D; Laird E; Ward M; Hoey L; Hughes CF; Strain JJ; Cunningham C; Healy M; Molloy AM; McNulty H; Lannon R; McCarroll K
Bone; 2024 Jul; 184():117108. PubMed ID: 38642819
[TBL] [Abstract][Full Text] [Related]
7. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals.
Maggio M; Lauretani F; Ceda GP; De Vita F; Bondi G; Corsonello A; Cattabiani C; Lattanzio F; Ruggiero C; Nouvenne A; Meschi T; Bandinelli S; Ferrucci L
Bone; 2013 Dec; 57(2):437-42. PubMed ID: 24076021
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
9. Chronic proton pump inihibitor therapy and calcium metabolism.
Yang YX
Curr Gastroenterol Rep; 2012 Dec; 14(6):473-9. PubMed ID: 23054811
[TBL] [Abstract][Full Text] [Related]
10. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
[TBL] [Abstract][Full Text] [Related]
11. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study.
Fraser LA; Leslie WD; Targownik LE; Papaioannou A; Adachi JD;
Osteoporos Int; 2013 Apr; 24(4):1161-8. PubMed ID: 22890365
[TBL] [Abstract][Full Text] [Related]
12. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study.
Abtahi S; Driessen JHM; Burden AM; Souverein PC; van den Bergh JP; van Staa TP; Boonen A; de Vries F
Ann Rheum Dis; 2021 Apr; 80(4):423-431. PubMed ID: 33310727
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
Park JH; Song YM; Jung JH; Han K
Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
[TBL] [Abstract][Full Text] [Related]
14. The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study.
Misra PS; Alam A; Lipman ML; Nessim SJ
BMC Nephrol; 2015 Aug; 16():136. PubMed ID: 26268579
[TBL] [Abstract][Full Text] [Related]
15. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
Hart E; Dunn TE; Feuerstein S; Jacobs DM
Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
[TBL] [Abstract][Full Text] [Related]
16. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.
Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ
J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040
[TBL] [Abstract][Full Text] [Related]
17. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes.
Chou YS; Jiang HJ; Chen CH; Ho PS; Lee TC
Sci Rep; 2020 Aug; 10(1):14081. PubMed ID: 32826941
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study.
Min YW; Lee YC; Kim K; Ryu S; Hong KS; Jeon HH; Kim YS; Park JH; Son HJ; Rhee PL
Korean J Intern Med; 2020 Sep; 35(5):1084-1093. PubMed ID: 31671930
[TBL] [Abstract][Full Text] [Related]
20. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
Kendler DL; Marin F; Geusens P; López-Romero P; Lespessailles E; Body JJ; Minisola S
Bone; 2020 Jan; 130():115113. PubMed ID: 31654779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]